Pro-hemostatic Therapy for Prevention and Treatment of Bleeding

  • M. Levi
  • R. Vink
  • E. de Jonge


The hemostatic system is able to swiftly convert fluid blood to a solid clot when there is a disruption of vascular integrity and bleeding occurs. Simultaneously, another important feature of hemostasis is to maintain blood fluidity within the blood vessel to guarantee adequate circulation throughout the body. These two paradoxical functions of the coagulation system can only be executed when, under physiological circumstances, there is a balance between low-level ongoing basal coagulation activation and permanent anticoagulation by both physiological anticoagulant mechanisms and fibrin removal as a function of the fibrinolytic system. Pharmacological agents may interfere in this balance, for example by inhibiting coagulant activity or promoting anticoagulant mechanisms, and indeed this type of treatment has proven to be effective in the prevention and treatment of thrombotic disease. Similarly, other agents are capable of promoting hemostasis or fibrin formation, or can block fibrinolytic activity. These so-called ‘pro-hemostatic agents’ may be useful in the prevention and treatment of bleeding in patients with coagulation defects, but also in patients with an a priori normal coagulation system, who experience severe (post-operative) bleeding or are to undergo procedures known to be associated with major blood loss [1]. In this chapter, we will discuss the aims and potential risks of pro-hemostatic therapy, the various agents with a pro-hemostatic potential and the efficacy of pro-hemostatic drugs to reduce perioperative blood loss or treat excessive (postoperative) bleeding.


Coagulation Factor Tranexamic Acid Massive Transfusion Coagulation Defect Primary Hemostasis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mannucci PM (1998) Hemostatic drugs. N Engl J Med 339: 245–253PubMedCrossRefGoogle Scholar
  2. 2.
    Levi M, van der Poll T (2000) Hemostasis and coagulation. In: Norton JA, Bollinger RA, Chang AE, Lowry SF (eds) Surgery: Scientific Basis and Current Practice. Springer, New York, pp 161–176Google Scholar
  3. 3.
    Francis JL (1992) The use of drugs to reduce blood loss during surgery. Hematol Rev 7: 85–99.Google Scholar
  4. 4.
    Marder VJ, Butler FO, Barlow GH (1994) Antifibrinolytic therapy. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J.W. Lippincott, Philadelphia, pp 795–814Google Scholar
  5. 5.
    Edmunds LH, Salzman EW (1994) Hemostatic problems, transfusion therapy, and cardiopulmonary bypass in surgical patients. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J.W. Lippincott, Philadelphia, pp 1031–1045Google Scholar
  6. 6.
    Limentani SA, Roth DA, Furie BC, Furie B (1993) Recombinant blood clotting proteins for hemophilia therapy. Semin Thromb Hemost 19: 62–72PubMedCrossRefGoogle Scholar
  7. 7.
    Richardson DW, Robinson AG (1985) Desmopressin. Ann Intern Med 103: 228–239CrossRefGoogle Scholar
  8. 8.
    Mannucci PM (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90: 2515–2521PubMedGoogle Scholar
  9. 9.
    Mannucci PM, Remuzzi G, Pusinri F, et al (1983) De-amino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308: 8–12PubMedCrossRefGoogle Scholar
  10. 10.
    Agnelli G, Parise P, Levi M, Cosmi B, Nenci GG (1995) Effects of desmopressin on hemostasis in patients with liver cirrhosis. Haemostasis 25: 241–247PubMedGoogle Scholar
  11. 11.
    Hedner U (1998) Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 9 (suppl 1): 5147–5152Google Scholar
  12. 12.
    Roberts HR (1998) Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 9 (suppl 1): S115–S118PubMedGoogle Scholar
  13. 13.
    Friederich PW, Weyer PC, Briet E, Doorenbos CJ, Levi M (2001) Succesful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 66: 292–294PubMedCrossRefGoogle Scholar
  14. 14.
    ten Cate H, Bauer KA, Levi M, et al (1993) The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 92: 1207–1212PubMedCrossRefGoogle Scholar
  15. 15.
    Friederich PW, Levi M, Bauer KA, et al (2001) Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 103: 2555–2559PubMedCrossRefGoogle Scholar
  16. 16.
    Hoffman M, Monroe DM, Roberts HR (1998) Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9 (suppl 1): S61–S65PubMedGoogle Scholar
  17. 17.
    Friederich PW, Geerdink MG, Spataro M, et al (2000) The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagul Fibrinolysis 11 (suppl 1): S129–132PubMedCrossRefGoogle Scholar
  18. 18.
    Harker LA (1986) Bleeding after cardiopulmonary surgery. N Engl J Med 314: 1446–1448.PubMedCrossRefGoogle Scholar
  19. 19.
    Levi M, Cromheecke ME, de Jonge E, et al (1999) Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354: 1940–1947PubMedCrossRefGoogle Scholar
  20. 20.
    Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O’Connor GT, Dacey LJ (1999) Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis. Circulation 99: 81–89PubMedCrossRefGoogle Scholar
  21. 21.
    Fremes SE, Wong BI, Lee E, et al (1994) Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 58: 1580–1588PubMedCrossRefGoogle Scholar
  22. 22.
    Laupacis A, Fergusson D (1997) Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion ( ISPOT) Investigators. Anesth Analg 85: 1258–1267PubMedGoogle Scholar
  23. 23.
    van der Meer J, Hillege HL, Kootstra GJ, et al (1993) Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Lancet 342: 257–264PubMedCrossRefGoogle Scholar
  24. 24.
    Lentschener C, Benhamou D, Mercier FJ (1997) Aprotinin reduces blood loss in patients undergoing elective liver resection. Anest Analg 84: 875–881Google Scholar
  25. 25.
    Porte RJ, Molenaar IQ, Begliomini B, et al (2000) Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 355: 1303–1309PubMedCrossRefGoogle Scholar
  26. 26.
    Levi M, ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341: 586–592PubMedCrossRefGoogle Scholar
  27. 27.
    de Jonge E, Levi M, Berends F, et al (1998) Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost 79: 286–290PubMedGoogle Scholar
  28. 28.
    Lim RC, Olcott C, Robinson AJ (1973) Platelet response and coagulation changes following massive blood replacement. J Trauma 18: 577–581CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • M. Levi
  • R. Vink
  • E. de Jonge

There are no affiliations available

Personalised recommendations